RBR-9v9r6vj
Recruiting
未知
Evaluation of the effectiveness of Cardioprotective Nutrition in patients with Metabolic Syndrome and High Blood Pressure: a randomized clinical trial
niversidade do Estado da Bahia - UNEB0 sitesApril 12, 2024
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversidade do Estado da Bahia - UNEB
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults and elderly people. Both sexes. Minimum age of 20 years. Diagnosis of hypertension (140 and/or 90 mmHg). Patients with metabolic syndrome. based on the IDF diagnosis (International Diabetes Federation, 2006\)
Exclusion Criteria
- •Pregnant women;nursing mothers; patients with severe heart failure;undergoing gastroplasty;with liver and/or kidney failure;previous history of encephalopathy or anasarca;with any and all neurocognitive conditions or with mental disorders (defined by their clinical history) will not be included in the research. or in clinical investigation); transplanted patients;patients with gastroplasty and those who have a life expectancy equal to or less than 6 months (eg those with malignant metastasis); wheelchair users, patients undergoing treatment for all and
- •any type of cancer and those with difficulties to feed orally
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluation of the effects of the cardioprotective diet on prevention of the incidence of cardiotoxicitycardiotoxicity in patients with breast cancer receiving Anthracycline.Malignant NeoplasmsC00-C97IRCT20131218015860N7School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes60
Completed
Not Applicable
Cardiovascular risk reduction study: supported by an integrated dietary approachISRCTN92382106King's College London (KCL) (UK)196
Not yet recruiting
Not Applicable
A clinical trial to study the cardioprotective effect of remote ischemic preconditioning in acute coronary syndrome patientsHealth Condition 1: I228- Subsequent ST elevation (STEMI) myocardial infarction of other sitesCTRI/2023/10/058663Department of Health Research
Active, not recruiting
Phase 1
Evaluation of the protective effect on the heart of a betablocker drug, nebivolol, in patients with breast cancer or diffuse B-cell lymphoma for which anthracyclinic chemotherapy has been plannedTo prevent cardiotoxicity of chemotherapeutic agents (anthracyclines)MedDRA version: 20.1Level: PTClassification code 10008444Term: Chemotherapy cardiotoxicity attenuationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2017-004618-24-ITIRCCS ISTITUTO CLINICO HUMANITAS80
Completed
Not Applicable
Comparative analysis of two solutions for miocardial protection in the correction of congenital cardiopathies.Children with acyanogenic congenital heart defects operated for total correctionTraced problems - Myocardial damageSpecific descriptors - Interventricular communication, Atrioventricular communication, Right ventricle with double outlet, Tetralogy of Fallot, Myocardial protection.Q21.0Q21.2Q20.1Q21.3C14.280H02.403.670C14.280.647C14.280.671RBR-9wqbx9Hospital do Coração de Messejana Dr. Carlos Alberto Studart Gomes